Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERCURY study of inebilizumab in autoimmune hepatitis
CTR20262933Phase 3Active
- Sponsor
- Amgen
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of inebilizumab in autoimmune hepatitis (AIH), sponsored by Amgen. Started Jul 2026; status: active.
02
Drugs
inebilizumab
03
Conditions
autoimmune hepatitis (AIH)
Beyond the preview
Go deeper on CTR20262933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262933.